Case Study: Critical Milestones Achieved Ahead of Schedule in Lung Cancer Study

lung cancer studyLow screen failures, strong communication and collaboration lead to swift site initiation and rapid enrollment

Novella Clinical was selected by a biotechnology company preparing to launch an international Phase III clinical trial for its investigational anaplastic lymphoma kinase (ALK) inhibitor in patients with non-small cell lung cancer (NSCLC). As this was a highly competitive space with more than five companies pursuing the same market, the sponsor’s clinical operations team was seeking an oncology-focused partner who could support protocol design and accelerate the start-up process to meet enrollment milestones quickly. Novella’s Oncology Division leveraged our extensive NSCLC operational experience, global footprint, and strategic resources from our parent company, IQVIA, to execute this large Phase III study.